Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Net Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Net Margin over the past 16 years, most recently at 5.62% for Q2 2025.

  • Quarterly results put Net Margin at 5.62% for Q2 2025, up 1308.0% from a year ago — trailing twelve months through May 2025 was 34.42% (down 5362.0% YoY), and the annual figure for FY2025 was 34.42%, down 4379.0%.
  • Net Margin for Q2 2025 was 5.62% at Lifecore Biomedical, Inc. \De\, up from 49.44% in the prior quarter.
  • Over the last five years, Net Margin for LFCR hit a ceiling of 47.16% in Q4 2023 and a floor of 183.73% in Q2 2022.
  • Median Net Margin over the past 5 years was 15.98% (2021), compared with a mean of 33.38%.
  • Biggest five-year swings in Net Margin: plummeted -17909bps in 2022 and later soared 17639bps in 2023.
  • Lifecore Biomedical, Inc. \De\'s Net Margin stood at 179.75% in 2021, then surged by 91bps to 16.49% in 2022, then skyrocketed by 386bps to 47.16% in 2023, then tumbled by -157bps to 26.73% in 2024, then skyrocketed by 79bps to 5.62% in 2025.
  • The last three reported values for Net Margin were 5.62% (Q2 2025), 49.44% (Q1 2025), and 26.73% (Q4 2024) per Business Quant data.